Literature DB >> 20650555

Immune hemolytic anemia associated with drug therapy.

George Garratty1.   

Abstract

Drug-induced immune hemolytic anemia (DIIHA) is rare; it can be mild or associated with acute severe hemolytic anemia (HA) and death. About 125 drugs have been implicated as the cause. The HA can be caused by drug-independent antibodies that are indistinguishable, in vitro and in vivo, from autoantibodies causing idiopathic warm type autoimmune hemolytic anemia (AIHA). More commonly, the antibodies are drug-dependent (i.e., will only react in vitro in the presence of the drug). The most common drugs to cause DIIHA are anti-microbials (e.g., cefotetan, ceftriaxone and piperacillin), which are associated with drug-dependent antibodies. The most common drug to cause AIHA is fludarabine. Finding out which drug is causing the problem and stopping that drug is the first approach to therapy. It is not easy to identify the drug interactions accurately in vitro; laboratories specializing in this area can be of great help. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20650555     DOI: 10.1016/j.blre.2010.06.004

Source DB:  PubMed          Journal:  Blood Rev        ISSN: 0268-960X            Impact factor:   8.250


  48 in total

1.  Development of Delayed Hemolytic Anemia After Treatment with Oral Artemether-Lumefantrine in Two Patients with Severe Falciparum Malaria.

Authors:  Yasuhiro Tsuchido; Fukumi Nakamura-Uchiyama; Kasumi Toyoda; Moritoshi Iwagami; Kentaro Tochitani; Koh Shinohara; Naokuni Hishiya; Taku Ogawa; Kenji Uno; Kei Kasahara; Yukiteru Ouji; Shigeyuki Kano; Keiichi Mikasa; Tsunehiro Shimizu; Masahide Yoshikawa; Haruhiko Maruyama
Journal:  Am J Trop Med Hyg       Date:  2017-02-13       Impact factor: 2.345

2.  Apomorphine-Induced Immune Hemolytic Anemia.

Authors:  Begoña Venegas Pérez; Teresa Arquero Portero; María Soledad Sánchez Fernández; Cici Feliz Feliz; Javier Del Val Fernández; Pedro José García-Ruiz
Journal:  Mov Disord Clin Pract       Date:  2016-06-06

3.  Severe drug-induced immune haemolytic anaemia due to ceftazidime.

Authors:  Fei Chen; Zhuying Zhan
Journal:  Blood Transfus       Date:  2014-03-19       Impact factor: 3.443

4.  Autologous Blood Transfusion as a Life Saving Measure for a Trauma Patient with Fracture Femur and Drug Induced Hemolytic Anemia: A Case Report.

Authors:  Sumit Vishwakarma; Rahul Chaurasia; Arulselvi Subramanian; Vivek Trikha; Kabita Chatterjee
Journal:  Indian J Hematol Blood Transfus       Date:  2016-08-25       Impact factor: 0.900

5.  Haemolytic anaemia in an HIV-infected patient with severe falciparum malaria after treatment with oral artemether-lumefantrine.

Authors:  Angela Corpolongo; Pasquale De Nardo; Piero Ghirga; Elisa Gentilotti; Rita Bellagamba; Chiara Tommasi; Maria Grazia Paglia; Emanuele Nicastri; Pasquale Narciso
Journal:  Malar J       Date:  2012-03-27       Impact factor: 2.979

Review 6.  Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch.

Authors:  Brian A Baldo; Nghia H Pham
Journal:  Cancer Metastasis Rev       Date:  2013-12       Impact factor: 9.264

7.  Haemolytic anaemia after oral artemether-lumefantrine treatment in a patient affected by severe imported falciparum malaria.

Authors:  P De Nardo; A Oliva; M L Giancola; P Ghirga; P Mencarini; M Bibas; E Nicastri; A Antinori; A Corpolongo
Journal:  Infection       Date:  2013-04-04       Impact factor: 3.553

8.  Epidemiology of drug hypersensitivity reactions using 6-year national health insurance claim data from Korea.

Authors:  JaeEun Han; Young-Min Ye; Sukhyang Lee
Journal:  Int J Clin Pharm       Date:  2018-04-02

9.  Ulcerated tophaceous gout.

Authors:  Michelle Gita Filanovsky; Kumar Sukhdeo; Megan Cunnane McNamara
Journal:  BMJ Case Rep       Date:  2015-08-03

10.  Puerarin-induced immune hemolytic anemia.

Authors:  Fei Chen; Shangqin Liu; Jiang Wu
Journal:  Int J Hematol       Date:  2013-05-10       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.